It has been estimated by the World Health Organization that PCOs affects 116 million women worldwide as of 2010 (3.4% of women). In the United States hyperthyroidism affects about 1.2% of the population. About half of these cases have obvious symptoms while the other half do not. The disease is more common in those over the age of 60 years. These two disorders are clinically associated. The aim of our research is to model the SHBG protein and to validate the 3D structure using insilico software and tools. Identification of the potential protein target is a basic step in structure-based drug designing. The modelled SHBG protein is involved in both PCOs and hypothyroidism. In our future studies, we shall use this modelled protein to introduce the novel drug candidate using molecular drug docking studies.